Literature DB >> 12465066

Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism.

Andrew Feigin1, Angelo Antonini, Masafumi Fukuda, Roberta De Notaris, Riccardo Benti, Gianni Pezzoli, Marc J Mentis, James R Moeller, David Eidelberg.   

Abstract

Positron emission tomography (PET) and network analysis have been used to identify a reproducible pattern of regional metabolic covariation that is associated with idiopathic Parkinson's disease (PD). The activity of this PD-related pattern can be quantified in individual subjects and used to discriminate PD patients from atypical parkinsonians. Because PET is not commonly available, we sought to determine whether similar discrimination could be achieved using more routine single photon emission computed tomography (SPECT) perfusion methods. Twenty-three subjects with PD (age, 63 +/- 9 years), 22 subjects with multiple system atrophy (MSA; age, 64 +/- 7 years), and 20 age-matched healthy controls (age, 62 +/- 13 years) underwent SPECT imaging of regional cerebral perfusion with Tc-99m ethylene cysteinate dimer (ECD). Using network analysis, we determined whether a PD-related pattern existed in the SPECT data, and whether its expression discriminated PD from MSA patients. Additionally, we compared the accuracy of group discrimination achieved by this pattern with that of the PET-derived PD-related pattern applied to the SPECT data. Network analysis of the SPECT data identified a significant pattern characterized by relative increases in cerebellar, lentiform, and thalamic perfusion covarying with decrements in the frontal operculum and in the medial temporal cortex. Subject scores for this pattern discriminated PD patients from controls (P < 0.01) and from MSA patients (P < 0.03). Subject scores for the PET-derived PD-related pattern computed in the individual SPECT scans more accurately distinguished PD patients from controls (P < 0.005) and from MSA patients (P = 0.0002). A significant PD-related covariance pattern can be identified in SPECT perfusion data. Moreover, the disease related pattern identified previously with PET can be applied to individual SPECT perfusion scans to provide group discrimination between PD patients, healthy controls, and individuals with MSA. Because of significant individual subject overlap between groups, however, the clinical utility of this method in the differential diagnosis of Parkinsonism remains uncertain. Copyright 2002 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12465066     DOI: 10.1002/mds.10270

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  30 in total

1.  Metabolic brain networks associated with cognitive function in Parkinson's disease.

Authors:  Chaorui Huang; Paul Mattis; Chengke Tang; Kenneth Perrine; Maren Carbon; David Eidelberg
Journal:  Neuroimage       Date:  2006-11-17       Impact factor: 6.556

Review 2.  Brain SPECT imaging in multiple system atrophy.

Authors:  R Cilia; G Marotta; R Benti; G Pezzoli; A Antonini
Journal:  J Neural Transm (Vienna)       Date:  2005-12       Impact factor: 3.575

Review 3.  Evidence from biomarkers and surrogate endpoints.

Authors:  Andrew Feigin
Journal:  NeuroRx       Date:  2004-07

4.  Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility.

Authors:  Yilong Ma; Chengke Tang; Phoebe G Spetsieris; Vijay Dhawan; David Eidelberg
Journal:  J Cereb Blood Flow Metab       Date:  2006-06-28       Impact factor: 6.200

Review 5.  The assessment of neurological systems with functional imaging.

Authors:  David Eidelberg
Journal:  Brain Lang       Date:  2006-08-08       Impact factor: 2.381

6.  Regional CBF changes in Parkinson's disease: the importance of functional neuroimaging analyses.

Authors:  Bárbara J Amorim; Erica C S Camargo; Elba C S C Etchebehere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09       Impact factor: 9.236

Review 7.  Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease.

Authors:  Shigeki Hirano; Thomas Eckert; Toni Flanagan; David Eidelberg
Journal:  Mov Disord       Date:  2009       Impact factor: 10.338

8.  Abnormal metabolic network activity in REM sleep behavior disorder.

Authors:  Florian Holtbernd; Jean-François Gagnon; Ron B Postuma; Yilong Ma; Chris C Tang; Andrew Feigin; Vijay Dhawan; Mélanie Vendette; Jean-Paul Soucy; David Eidelberg; Jacques Montplaisir
Journal:  Neurology       Date:  2014-01-22       Impact factor: 9.910

9.  Changes in network activity with the progression of Parkinson's disease.

Authors:  Chaorui Huang; Chengke Tang; Andrew Feigin; Martin Lesser; Yilong Ma; Michael Pourfar; Vijay Dhawan; David Eidelberg
Journal:  Brain       Date:  2007-04-30       Impact factor: 13.501

Review 10.  Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome.

Authors:  José Fidel Baizabal-Carvallo; Cecilia Bonnet; Joseph Jankovic
Journal:  J Neural Transm (Vienna)       Date:  2013-04-13       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.